Skip to main content
ChengDa Pharmaceuticals Co.,Ltd. logo

ChengDa Pharmaceuticals Co.,Ltd. - Investor Relations & Filings

Listed IPO Jan 2022
Ticker · 301201 ISIN · CNE100005766 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 459 across all filing types
Latest filing 2025-11-12 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301201 · 1 venue

Key figures FY2024

Period ended 2024-12-31 · CNY
Headline annual figures for ChengDa Pharmaceuticals Co.,Ltd., fiscal year 2024, reported in CNY, with the source filing for each figure.
Total Revenues CNY 333.13M per the Audit Report / Information filed 2025-04-24
Net Income CNY -27.64M per the Audit Report / Information filed 2025-04-24
Total Assets CNY 2.44B per the Audit Report / Information filed 2025-04-24
Total Equity CNY 2.15B per the Audit Report / Information filed 2025-04-24
Cash from Ops CNY 28.65M per the Audit Report / Information filed 2025-04-24

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About ChengDa Pharmaceuticals Co.,Ltd.

https://www.chengdapharm.com

ChengDa Pharmaceuticals Co., Ltd. specializes in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company maintains a diverse product portfolio with a significant focus on the L-carnitine series, including levocarnitine and its derivatives, serving as a major global supplier. Its therapeutic areas of expertise encompass cardiovascular health, metabolic disorders, and anti-infective treatments. ChengDa Pharmaceuticals operates advanced production facilities that adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications from regulatory bodies such as the FDA and EDQM. The organization emphasizes technological innovation and process optimization to provide high-purity chemical components for the global market, supporting both generic and proprietary drug development.

Recent filings

Filing Released Lang Actions
关于选举第六届董事会职工代表董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of an employee representative director to the company's sixth board of directors. It includes details about the election process, compliance with relevant laws and regulations, and a biography of the elected director. There is no financial data, audit information, or report content. The document is clearly about board/management information, specifically changes in the company's board composition. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, not a report or announcement of a report publication.
2025-11-12 Chinese
关于完成董事会换届选举及聘任高级管理人员、证券事务代表的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the completion of the board of directors' re-election and the appointment of senior management and securities affairs representatives. It details the composition of the new board, committees, and senior management personnel, including their qualifications and compliance with relevant laws and regulations. It also mentions the departure of previous directors and supervisors. The document is a formal disclosure of changes in the company's board and senior management rather than a report or financial statement. Therefore, it fits the category of Board/Management Information (MANG). The document length (5648 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive announcement of management changes.
2025-11-12 Chinese
北京中伦文德（杭州）律师事务所关于诚达药业股份有限公司2025年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and procedures of a company's 2025 second extraordinary general meeting of shareholders. It details the convening, attendance, voting procedures, and results of the shareholder meeting, including election of board members and amendments to company governance documents. The document is not a full annual report, audit report, or financial statement, but rather a legal opinion on the shareholder meeting and its resolutions. It contains detailed voting results and legal compliance statements related to the shareholder meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of a shareholder meeting. The document length is over 10,000 characters and contains substantive content, not just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2025-11-12 Chinese
2025年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 second extraordinary shareholders' meeting of Chengda Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals including amendments to company bylaws and election of board members, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on official voting results from a shareholders' meeting rather than the meeting materials or presentations themselves. It is not a full annual or interim report, nor an earnings release or management discussion. The document is not a proxy solicitation or a report publication announcement. Given the detailed voting results and resolutions passed, this fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (7060 characters) supports it being a full announcement rather than a brief notice or certification. Therefore, the classification is DVA with high confidence.
2025-11-12 Chinese
第六届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the first meeting of the sixth board of directors of Chengda Pharmaceutical Co., Ltd. It details the election of the chairman, appointment of senior management, and committee memberships. The document includes voting results and references to a related announcement (2025-046) for further details. There is no financial data, earnings information, or report content. The document is clearly about board and management changes and appointments, fitting the category of Board/Management Information (MANG). The document length is 2267 characters, which is consistent with an announcement rather than a full report.
2025-11-12 Chinese
关于召开2025年第二次临时股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement about the convening of the 2025 second extraordinary general meeting (临时股东大会) of Chengda Pharmaceutical Co., Ltd. It includes information about the meeting time, location, agenda items, voting procedures, and proxy forms. The content focuses on the organization and procedural details of a shareholders' meeting rather than the results of voting or the meeting itself. It does not contain voting results or financial reports. Therefore, it is an announcement related to the meeting itself, not the voting results or the meeting materials. According to the filing definitions, this fits best under AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. Although this is an extraordinary meeting, the category AGM-R is the closest match for meeting-related announcements and materials. The document is over 5,000 characters and contains substantive meeting information, so it is not a mere report publication announcement or regulatory filing. Hence, the classification is AGM-R with high confidence.
2025-11-10 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.